Chelsea halves workforce to focus on Northera approval trial
This article was originally published in Scrip
Chelsea Therapeutics founder, president and CEO Simon Pedder has resigned and the company said on 10 July that it will cut its workforce nearly in half to reduce expenses and focus its resources on a single goal: US FDA approval for Northera (doxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (neurogenic OH).
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.